Skip to Content
COVID-19 Resources
NIH - National Institutes of Health National Cancer Institute Division of Cancer Treatment and Diagnosis Center for Cancer Research
Developmental Therapeutics Clinic (DTC)
Contact NExT
Show menu
Search this site
Last Updated: 03/04/20

Our Team — Faces of the DTC

Staff photo of the DTC Team

Top Row – Left to Right: Laura Corado, Kathleen Pogonowski, Amisha Shah, Sharon Allison, Jennifer Zlott, Nancy Moore, Ashley Bruns, Corey Evans

Bottom Row – Left to Right: Geraldine O’Sullivan Coyne, MD, PhD, Sheila Prindiville, MD, Naoko Takebe, MD, PhD, Sabrina Khan, MD, Arjun Mittra, MD, Alice Chen, MD, Chris St-Clair, Cecilia Monge Bonilla, MD, James Doroshow, MD

Primary Investigators

  • Image of James H. Doroshow, MDJames H. Doroshow, MD, is the Deputy Director for Clinical and Translational Research of the National Cancer Institute and the Director of NCI’s Division of Cancer Treatment and Diagnosis. He is the author of over 400 full-length publications in the areas of molecular pharmacology, the role of oxidant stress in tumor cell signal transduction, and novel therapeutic approaches to solid tumors; he is also the Associate Editor for Oncology of the 25th Edition of the Cecil Textbook of Medicine. Following an Internal Medicine residency at the Massachusetts General Hospital, he completed a fellowship in Medical Oncology at the Medicine and Clinical Pharmacology Branches of the National Cancer Institute, NIH.
  • Image of Alice Chen, MDAlice Chen, MD, has wide-ranging experience in medical oncology and hematology over a 25+ year career. In 2015, she became the Head of the Early Clinical Trials Development Program and the Developmental Therapeutics Clinic. Her clinical experience of almost three decades includes over 15+ years as a clinical researcher participating both as primary and associate investigator of many early phase trials, including the first ever phase "0" trial performed under the FDA's Exploratory IND as well as "first in man" phase 1 trials. During her time in private practice in Corpus Christi, TX, she was voted Super Doctor by Texas Magazine in 2004 and 2005. She is currently the primary investigator for the Molecular Profiling-based Assignment of Cancer Therapy (MPACT) and co-primary investigator for the nationwide Molecular Analysis for Therapy Choice (MATCH) trial, both part of the NCI Precision Medicine Initiative. She has co-authored over 60 peer-reviewed publications. She is the recipient of 8 NIH Awards of Merit for her contribution to international relationships, adverse event reporting, CTCAE, PRO-CTCAE, and NCI-MATCH.
  • Image of Geraldine O’Sullivan Coyne, MD, PhDGeraldine O’Sullivan Coyne, MD, PhD is a Staff Clinician in the Early Clinical Trials Development Program and a Faculty member since joining DTC in 2016. She obtained exceptional clinical training at several excellent programs and institutions prior to joining the team. She was awarded her PhD in Molecular Medicine from University College Cork, Ireland, in 2010, and she also holds a diploma in Health Care Management from the Smurfit Graduate Business School at University College Dublin. She is a member of the NCI Exceptional Responder Initiative, an associate investigator for NCI-MPACT, and leads a number of early phase trials. Most recently, she was awarded the Society of Connective Tissue Oncology (CTOS) Young Investigator in 2018 for her work with immunotherapy in a rare sarcoma subtype. At DTC she continues to pursue her interest in developing novel cancer therapies using pharmacokinetic and pharmacodynamic tools to impulse drug development.
  • Image of Naoko Takebe, MD, PhDNaoko Takebe, MD, PhD, joined the Developmental Therapeutics Clinic as an Associate Chief, Translational Science Section Head of the Early Clinical Trials Development Program in June 2017. Prior to this, she was a Senior Investigator at the Cancer Therapy Evaluation Program (CTEP) for nearly 10 years, where she implemented early clinical trials under CRADA with pharmaceutical and bio-venture companies. Prior to joining NCI, she was a faculty member in the Department of Medicine and Pathology at the University of Maryland School of Medicine, Blood and Stem Cell Transplant Program, conducted clinical trials, and worked as a laboratory principal investigator (PI). Dr. Takebe received her M.D. and Ph.D. degrees from Hirosaki University School of Medicine, Japan. She completed internal medicine residency programs (U.S. Naval Hospital in Yokosuka, Keio University Hospital in Tokyo and California Pacific Medical Center in San Francisco) and medical and post-doctoral fellowships (Memorial Sloan-Kettering Cancer Center). Currently, she is also a Translational Science PI for the NCI Exceptional Responder Initiative, a NCI co-investigator for NCI-MATCH and Pediatric MATCH, and a member of the NCI Provocative Question team and Cancer Moonshot Initiatives. She is board certified in Hematology and Medical Oncology.
  • Image of Arjun Mittra, MDArjun Mittra, MD joined the Early Clinical Trials Development Program and the Developmental Therapeutics Clinic in July 2018 as an advanced fellow. After receiving his medical degree in India, Dr. Mittra pursued laboratory research training in Oncology at Memorial Sloan-Kettering Cancer Center and at the University of Southern California. He completed residency training at the Texas Health Presbyterian Hospital Dallas and specialty clinical training in Hematology/Oncology at the Mayo Clinic in Jacksonville, Florida. Dr. Mittra brings his experience in laboratory research and clinical oncology to the DTC and will be pursuing his interest in drug development and early phase clinical trials.
  • Image of Sabrina Khan MD, MPHSabrina Khan MD, MPH is a hematology and oncology fellow at the National Institutes of Health. She received her BS in Physics from Yale University and her MD from the Yale School of Medicine. She completed Internal Medicine residency at the Albert Einstein College of Medicine/Montefiore Medical Center. Dr. Khan also has a strong interest in global health and received an MPH from the University of London’s School of Hygiene and Tropical Medicine. Dr. Khan’s previous research has been in bioinformatics and an early phase clinical trial in breast cancer. Her career interest is in drug development.
  • Image of Abdul Rafeh Naqash, MDAbdul Rafeh Naqash, MD joined the Early Clinical Trials Development Program and the Developmental Therapeutics Clinic in July 2019 as an advanced fellow. After receiving his medical degree at Government Medical College Srinagar, Kashmir, Dr. Naqash pursued short-term research training at the National Institute of Immunology, New Delhi and at the University of Buffalo, NY. He completed internal medicine residency training at the University of Buffalo/Catholic Health. Subsequently Dr. Naqash completed his sub-specialty clinical training in Hematology/Oncology at East Carolina University, Greenville, NC. At the DTC, Dr Naqash is focusing his interest in drug development and incorporating a genomically driven approach to early phase drug trials.

Associate Investigators

  • Image of Elad Sharon, MD, MPHElad Sharon, MD, MPH, joined the NCI Cancer Therapy Evaluation Program (CTEP) in December 2011 as a Senior Investigator in the Investigational Drug Branch, where he works with academia and industry to develop promising cancer therapies. His portfolio includes antibody-drug conjugates, immune checkpoint inhibitors and other agents. Dr. Sharon co-directs immunotherapy trials at CTEP and serves as an attending physician in NCI's Developmental Therapeutics Clinic. Dr. Sharon is on program committees for several major oncology meetings. Dr. Sharon received his M.D. from Baylor College of Medicine in Houston, Texas in 2003. He completed his internal medicine residency at Emory University in 2006 and his Hematology/Oncology Fellowship at the NIH in 2011, while obtaining a Master of Public Health degree at the Harvard University in 2009. His fellowship research focused on clinical trials in mesothelioma. Dr. Sharon works on patterns of care projects with NCI’s Healthcare Delivery Research Program using SEER data and with NCI's Surveillance Research Program to evaluate emerging practice patterns and the economics of cancer care. He previously worked as a guest at the Brookings Institution. He is as an associate editor of JNCI Cancer Spectrum and on the editorial board of JCO Clinical Cancer Informatics.
  • Image of Howard Streicher, MDHoward Streicher, MD, received his Applied Baccalaureate degree in physics from Cornell University and his medical degree from New York University. He completed an internship and residency training in Internal Medicine at the New York University-Bellevue Medical Center and New York Veterans Hospital. He was on active duty with the United States Naval Reserve and a faculty member at the John Burns School of Medicine . He completed training in immunology at the University of Colorado and the Metabolism Branch of the National Cancer Institute before joining the Laboratory of Tumor Immunology National Cancer Institute. As a member of the Investigational Drug Branch of the Cancer Therapy Evaluation Program (CTEP) his portfolio centers on immunotherapeutic agents including vaccines, cytokines, and immune modulating agents for the treatment of cancer.
  • Image of Richard Piekarz, MD, PhDRichard Piekarz, MD, PhD, is a Medical Officer in the Investigational Therapeutics 3 Section of the Investigational Drug Branch of the Cancer Therapy Evaluation Program (CTEP). Dr. Piekarz is a graduate of the Albert Einstein College of Medicine, where he received a PhD in Molecular Pharmacology in addition to an MD. He did his internship and residency in Internal Medicine at the University Hospitals of Cleveland. Dr. Piekarz served as a Medical Oncology Fellow and then Senior Fellow at the NCI-Navy Medical Oncology program where he also served as a Staff Clinician prior to joining IDB. He is also a Preceptor at the Uniformed Services University of the Health Sciences (USUHS) Department of Pharmacology. Dr. Piekarz background includes the development of the HDAC inhibitors. This included demonstration of their efficacy in patients with T-cell lymphoma, conduction of a thorough analysis of its cardiac effects, and laboratory work to define their molecular effects and potential mechanisms of resistance.
  • Sheila A. Prindiville, MD, MPHSheila A. Prindiville, MD, MPH, is the Director of the Coordinating Center for Clinical Trials at NCI, an office that facilitates the integration and prioritization of clinical trials and translational research across the Institute. She received her MD from Northwestern University and her MPH from Johns Hopkins University. After finishing her residency in Internal Medicine at Evanston Hospital, she completed fellowships in both Medical Oncology and Cancer Prevention at NCI in 1995. She was on the faculty of the Division of Medical Oncology at the University of Colorado Health Sciences Center from 1996 – 2001. She subsequently returned to the intramural program of NCI in 2002 to direct the Genetics Branch’s Clinical Cancer Genetics Program until she assumed her present position in 2006. She is currently a member of the NIH Clinical Center staff and serves as an associate investigator in the Developmental Therapeutics Clinic.

Nurse Practitioners

  • Lamin Juwara is a Nurse Practitioner on the Developmental Therapeutics Team. Lamin received his Doctor of Nursing Practice degree at George Washington University and his Nurse Practitioner certification at the University of Maryland. Lamin has been at NIH since 2001.
  • Jessica Mukherjee, MS, CRNP is a nurse practitioner in the Developmental Therapeutics Clinic. She received her BS in Biology from the University of Virginia and her BSN in Nursing and MS in Adult-Gerontology Primary Care Nurse Practitioner from Columbia University. Prior to joining the DTC, she worked as a nurse practitioner in outpatient oncology and hematology. She is a member of the Sigma Theta Tau International Honor Society of Nursing. She also previously worked as a research specialist conducting laboratory-based infectious disease research, as well as a research technician working with patients with ALS.

Research Nurses

  • Ashley Bruns, RN, MSN, received her Bachelor's and Master's degree in nursing from the University of South Alabama in Mobile AL. Ashley has been a nurse since 2004 and an oncology research nurse since 2011.
  • Nancy Moore RN, MSN, is a Clinical Research Nurse on the Developmental Therapeutics Team. She received her Bachelor’s degree from Villanova University, PA and her graduate degree from Adelphi University in Long Island NY. She has been practicing in the area of clinical research trials for 20+ years.
  • Jennifer Zlott, RN, OCN is an oncology certified nurse. Her experience prior to joining the Developmental Therapeutics team includes working with intermediate cardiac care patients, as well as hematopoietic stem cell transplant and hematology/oncology patients.
  • Murielle Hogu, RN, MSN, received her BS from Post University and Master’s degree in Nursing from Walden University. Murielle has been an oncology nurse in the inpatient setting since 2010 and joined the Developmental Therapeutics Team in 2018.
  • Brooke Augustine, RN, BSN, received her Bachelor’s degree in nursing from Stevenson University in Maryland. Brooke has been an oncology nurse in the inpatient setting since 2014 and a research nurse since 2017 with a focus on phase I clinical trials.
  • Mary Jane Ong, RN, BSN, received her Bachelor’s degree in nursing from University of Maryland. Mary Jane has been involved in clinical trials for 15+ years and in oncology research since 2017.

Referral Coordinators

  • Theodore Crowder has been at the NIH for 13 years. He worked for more than 10 years on one of the in-patient units as a Program Support Assistant and won several awards in customer service. In November 2017, he joined the Early-Phase Developmental Therapeutics team at NCI.
  • Tanaya Allen joined the Early Phase Developmental Therapeutics team at NCI in May 2019. She has worked at NIH for 11 years as a Research Support Assistant on one of the busiest inpatient units in the hospital. Tanaya has won several awards, including those that recognize her continuous outstanding work in customer service.

Research Associates

  • Corey Evans is the PK/PD Specimen laboratory supervisor for DTC. Corey worked on the laboratory team in the Research Nexus, a GCRC lab supporting clinical trials and other basic research at the Medical University of South Carolina (MUSC). Prior to MUSC, he completed graduate studies at Virginia Commonwealth University, where he worked in neuroscience with a concentration in traumatic brain injury. He is originally from South Carolina and completed his undergraduate coursework at Clemson University.
  • Amisha Shah is a Clinical Protocol Coordinator with the Developmental Therapeutics Team, assisting with audit preparation and helping to ensure protocol compliance. She received her master’s degree in biomedical sciences from the University of Medicine and Dentistry in New Jersey. Prior to joining the DTC team, she worked as a clinical research associate.
  • Gurleen Kaur is a Clinical protocol Coordinator for the Developmental Therapeutics Clinic team who focuses primarily on regulatory affairs. She has worked with the team for more than 6 years, initially as a Data Manager and then a Data Manager Supervisor. She received her master’s degree in health administration and policy from the University of Maryland University College.
Clinical Trials Questions?
General Cancer Questions?